Acer Therapeutics Inc.

56 articles with Acer Therapeutics Inc.

• Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

  11/19/2021

  Acer Therapeutics Inc. today reported financial results for the third quarter ended September 30, 2021 and provided an update on Acer’s recent corporate developments.

• Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 FormulationKey ACER-001 formulation composition of matter patent strengthens proprietary position in U.S. until 2036

  10/26/2021

  Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new U.S. patent to Acer for certain claims related to ACER-001 (sodium phenylbutyrate).

• Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 FormulationNotice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036

  10/7/2021

  Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Acer’s patent application No. 17/196,416 for certain claims related to ACER-001 (sodium phenylbutyrate).

• Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle DisordersFDA sets PDUFA target action date of June 5, 2022

  10/6/2021

  Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief”), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for the treatment of patients with Urea Cycle Disorders (UCDs).

• Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

  8/30/2021

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference

• Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate Update

  8/10/2021

  Acer Therapeutics Inc., a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, reported financial results for the second quarter ended June 30, 2021 and provided an update on the Company’s recent corporate developments.

• RELIEF THERAPEUTICS Holdings AG: Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders

  8/9/2021

  Acer Therapeutics Inc., a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, and RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced the submission of a New Drug Application to the U.S. FDA for ACER-001 for the treatment of Urea Cycle Disorders.

• Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders

  8/9/2021

  Acer Therapeutics Inc. and RELIEF THERAPEUTICS Holding AG today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs).

• Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA Meeting

  6/10/2021

  Acer Therapeutics Inc. today announced that following a recent Type B meeting with the U.S. Food and Drug Administration (FDA) regarding Acer’s proposed EDSIVO™

• Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA

  5/25/2021

  Acer Therapeutics Inc. and RELIEF THERAPEUTICS Holding AG announced the outcome of Acer’s pre-New Drug Application meeting with the U.S. Food and Drug Administration for ACER-001 for the treatment of Urea Cycle Disorders.

• Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update

  5/17/2021

  Acer Therapeutics Inc., a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, reported financial results for the first quarter ended March 31, 2021 and provided an update on the Company’s recent corporate developments.

• 

  Philadelphia, Pacific Northwest See Surge in Biopharma Jobs

  5/14/2021

  Life science jobs are booming in several regions around the U.S. One is the Pacific Northwest, specifically Oregon; another is the Philadelphia area. Here’s a look.

• Acer Therapeutics to Participate in Needham Virtual Healthcare Conference

  3/29/2021

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming 20th Annual Needham Virtual Healthcare Conference

• Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

  3/22/2021

  Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021

• Acer Therapeutics to Participate in March Virtual Investor Conferences

  3/1/2021

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Life Sciences Virtual Conference

• Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  3/1/2021

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2020

• Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed ConditionsTargeting a pre-NDA meeting with FDA in Q2 2021

  2/11/2021

  Acer Therapeutics Inc., a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, announced topline results from its bioequivalence trial in which ACER-001 showed similar relative bioavailability compared to BUPHENYL® under fed conditions.

• Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001

  1/25/2021

  RELIEF THERAPEUTICS Holding AG today announced that the companies have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license agreement for worldwide development and commercialization for ACER-001.

• Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001

  1/25/2021

  Relief Therapeutics Holding AG (SIX: RLF, OTCQB: RLFTF)(“Relief”), a biopharmaceutical company with its lead compound RLF-100 TM  (aviptadil) in advanced clinical development to treat severe COVID-19 patients, and Acer Therapeutics today announced that the companies have signed an Option Agreement providing exclusivity for the right to negotiate a potential collaboration and license agreement for worldwide development and commercialization for ACER-001.

• Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle DisordersTopline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021

  12/22/2020

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of its pivotal trial evaluating the bioequivalence (BE) of ACER-001 compared to BUPHENYL® (sodium phenylbutyrate)